Skip to content
Cancer Institute NSW sites
eviQ Education
Learning resources for cancer staff
opens in a new tab or window
Cancer Institute NSW
NSW cancer control agency
opens in a new tab or window
Patient Information
Practical advice about cancer
opens in a new tab or window
Canrefer
Find a cancer specialist
opens in a new tab or window
BreastScreen NSW
Detect breast cancer early
opens in a new tab or window
Cervical Screening NSW
Cervical Screening NSW
opens in a new tab or window
iCanQuit
Learn how to quit smoking
opens in a new tab or window
Log in
Register
Search
Search
Log in
Register
Search
Main menu Toggle menu collaspe
Search eviQ
Close
Search
Search
Home
Home
Cancer genetics
Adult
Genetic testing for heritable pathogenic variants
Genetic testing using cancer gene panels
Risk management
Paediatric
Genetic testing for heritable pathogenic variants
Genetic testing using cancer gene panels
Risk management
Referral guidelines
Consumer information
Resources
Haematology and BMT
Leukaemias
Acute lymphoblastic leukaemia
Acute myeloid leukaemia
Acute promyelocytic leukaemia
Chronic lymphocytic leukaemia
Chronic myeloid leukaemia
Hairy cell leukaemia
Myelodysplastic disorders
Lymphoma
Hodgkin lymphoma
Burkitt lymphoma
Mantle cell lymphoma
NK-cell and T-cell lymphoma
Other B-cell lymphoma
Primary CNS lymphoma
Waldenstrom macroglobulinaemia
Multiple myeloma
Blood and marrow transplant
Mobilisation
Allogeneic
Autologous
GVHD prophylaxis
Cellular therapies
Medical oncology
Breast
Neoadjuvant/Adjuvant
Metastatic
Colorectal
Adjuvant and neoadjuvant
Metastatic
Anal
Rectal
Gynaecological
Cervical
Endometrial
Gestational trophoblastic disease
Ovarian
Vulval
Head and neck
Definitive chemoradiation
Induction chemotherapy
Nasopharyngeal
Post operative chemoradiation
Recurrent or metastatic
Salivary gland
Thyroid
Neurological
Glioma
Respiratory
Mesothelioma
Non small cell lung cancer - Adjuvant/neoadjuvant
Non small cell lung cancer - Advanced/metastatic
Small cell lung cancer
Sarcoma
Soft tissue sarcoma
Bone sarcoma
Skin
Melanoma neoadjuvant/adjuvant
Melanoma metastatic
Non-melanoma
Upper gastrointestinal
Gastric and oesophageal adjuvant and neoadjuvant
Gastric and oesophageal metastatic
Gastrointestinal stromal cell tumours
Hepatic
Neuroendocrine
Pancreas and biliary
Urogenital
Adrenocortical
Bladder and Urothelial
Prostate
Renal
Testicular
Penile
Rare cancers
Colorectal
Gynaecological
Head and neck
Melanoma
Neurological
Respiratory
Sarcoma
Upper gastrointestinal
Urogenital
Tumour-agnostic
Tumour-agnostic
Radiation oncology
Breast
Colorectal
Gynaecological
Haematology
Head and neck
Neurological
Palliative
Respiratory
Upper gastrointestinal
Urogenital
Bladder
Prostate
Kidney and adrenal
Skin
Stereotactic
Clinical resources
eviQ calculators
Aboriginal health workers
ADDIKD guideline
Administration of anti-cancer drugs
Assessment tools
BMT & cellular therapies
Central venous access devices (CVADs)
Day of Treatment Assessment
Extravasation
Pumps
Health professional fact sheets
Oncological emergencies
Radiation oncology
Assessment tools
Cardiac implantable electronic devices
Contrast administration
Radiation-induced dermatitis
Side effect and toxicity management
Side effect and toxicity management
Cardiovascular
Gastrointestinal
General
Genitourinary
Gynaecological
Haematological
Hair, skin and nails
Immunological
Neurological and sensory
Oropharyngeal
Prophylaxis and treatment
Reproductive
Respiratory
Telephone triage toolkit
Patients and carers
Anticancer drug treatments
Radiation therapy treatments
Cancer genetics information sheets
Patient information sheets
At home
Cancer type specifics
Complementary and alternative medicines
Eating and drinking
Fertility, sex, pregnancy and breastfeeding
Treating cancer with medicines
How you have anticancer medicine treatment
Treating cancer with radiation therapy
Managing side effects
Vaccinations
Your family and friends
Patient information in other languages
عربى (Arabic)
简 (Simplified Chinese)
繁 (Traditional Chinese)
Français (French)
Ελληνικά (Greek)
Italiano (Italian)
한국어 (Korean)
Español (Spanish)
Tiếng Việt (Vietnamese)
Македонски (Macedonian)
ไทย (Thai)
Patient information videos
Cancer Institute NSW sites
eviQ Education
Learning resources for cancer staff
opens in a new tab or window
Cancer Institute NSW
NSW cancer control agency
opens in a new tab or window
Patient Information
Practical advice about cancer
opens in a new tab or window
Canrefer
Find a cancer specialist
opens in a new tab or window
BreastScreen NSW
Detect breast cancer early
opens in a new tab or window
Cervical Screening NSW
Cervical Screening NSW
opens in a new tab or window
iCanQuit
Learn how to quit smoking
opens in a new tab or window
Home
Medical oncology
Urogenital
78 results
Search
Adrenocortical
Adrenocortical carcinoma metastatic EDP (etoposide DOXOrubicin ciSplatin) and mitotane
Bladder and Urothelial
Adjuvant nivolumab (flat dosing)
Advanced, metastatic or recurrent pembrolizumab
Bladder intravesical BCG (OncoTICE)
Bladder intravesical DOCEtaxel and gemcitabine
Bladder intravesical gemcitabine
Bladder intravesical mitomycin
Bladder intravesical mitomycin single dose post TURBT
Bladder/Urothelial adjuvant ddMVAC (dose dense methotrexate vinBLASTine DOXOrubicin ciSplatin)
Bladder/Urothelial fluorouracil and mitomycin chemoradiation
Bladder/Urothelial locally advanced definitive ciSplatin (weekly) chemoradiation
Bladder/Urothelial locally advanced or metastatic avelumab
Bladder/Urothelial locally advanced or metastatic cARBOplatin and gemcitabine
Bladder/Urothelial locally advanced or metastatic ciSplatin and gemcitabine
Bladder/Urothelial locally advanced or metastatic enfortumab vedotin
Bladder/Urothelial metastatic MVAC (methotrexate vinBLASTine DOXOrubicin ciSplatin)
Bladder/Urothelial neoadjuvant ddMVAC (dose dense methotrexate vinBLASTine DOXOrubicin ciSplatin)
Bladder/Urothelial neoadjuvant/adjuvant ciSplatin and gemcitabine
Bladder/Urothelial recurrent or metastatic DOCEtaxel
Bladder/Urothelial small cell cARBOplatin and etoposide
Bladder/Urothelial small cell ciSplatin and etoposide
Urothelial upper tract adjuvant cARBOplatin and gemcitabine
Bladder intravesical BCG (Connaught strain) SUPERSEDED
Bladder/Urothelial advanced vinflunine DISCONTINUED
Bladder/Urothelial locally advanced or metastatic cARBOplatin and gemcitabine (modified) (day 8 cARBOplatin) DISCONTINUED
Bladder/Urothelial neoadjuvant MVAC (methotrexate vinBLASTine DOXOrubicin ciSplatin) DISCONTINUED
Prostate
Advanced, metastatic or recurrent olaparib
Prostate darolutamide
Prostate enzalutamide
Prostate locally advanced or metastatic apalutamide
Prostate locally advanced or metastatic degarelix
Prostate metastatic bicalutamide
Prostate metastatic CABAZitaxel three weekly and prednisolone
Prostate metastatic CABAZitaxel, cARBOplatin and prednisolone
Prostate metastatic castration-resistant abiraterone and prednisolone
Prostate metastatic castration-resistant abiraterone micronised and methylprednisolone
Prostate metastatic castration-sensitive abiraterone and prednisolone
Prostate metastatic castration-sensitive abiraterone micronised and methylprednisolone
Prostate metastatic castration-sensitive DOCEtaxel three weekly
Prostate metastatic denosumab
Prostate metastatic DOCEtaxel three weekly and prednisolone
Prostate metastatic DOCEtaxel two weekly and prednisolone
Prostate metastatic goserelin
Prostate metastatic leuprorelin (Eligard)
Prostate metastatic leuprorelin (Lucrin)
Prostate metastatic triptorelin
Prostate metastatic zoledronic acid
Prostate metastatic cyproterone SUPERSEDED
Prostate metastatic flutamide SUPERSEDED
Prostate metastatic mitozantrone and prednisolone SUPERSEDED
Prostate metastatic DOCEtaxel weekly and prednisolone DISCONTINUED
Prostate metastatic nilutamide DISCONTINUED
Renal
Advanced or metastatic cABOZANtinib
Advanced or metastatic nivolumab (flat dosing)
Advanced or metastatic nivolumab (weight based dosing) SUPERSEDED
Metastatic nivolumab maintenance (flat dosing) following ipilimumab and nivolumab
Metastatic nivolumab maintenance (weight based dosing) following ipilimumab and nivolumab SUPERSEDED
Recurrent or metastatic leNVAtinib and pembrolizumab
Renal cell metastatic avelumab and aXITinib
Renal cell metastatic aXITinib
Renal cell metastatic everolimus
Renal cell metastatic ipilimumab and nivolumab (induction)
Renal cell metastatic pAZOPanib
Renal cell metastatic soRAFENib
Renal cell metastatic sUNITinib
Renal cell recurrent or metastatic cABOZANtinib and nivolumab
Renal cell metastatic beVACizumab and interferon alfa 2a DISCONTINUED
Renal cell metastatic interferon alfa 2a DISCONTINUED
Renal cell metastatic temsirolimus DISCONTINUED
Testicular
Autologous conditioning protocol germ cell tumour TICE treatment overview
Testicular germ cell advanced or metastatic EP (etoposide ciSplatin)
Testicular germ cell metastatic BEP (bleomycin etoposide ciSplatin)
Testicular germ cell metastatic VIP (etoposide iFOSFamide ciSplatin)
Testicular germ cell non seminoma adjuvant BEP (bleomycin etoposide ciSplatin)
Testicular germ cell recurrent TIP (PACLitaxel iFOSFamide ciSplatin)
Testicular germ cell recurrent VeIP (vinBLASTine iFOSFamide ciSplatin)
Testicular germ cell seminoma adjuvant cARBOplatin
Penile
Penile cancer PACLitaxel iFOSFamide ciSplatin
Title
Content